4-year Alzheimer's trial data just dropped - 69% of early-stage patients showed zero decline

The Clarity AD Open-Label Extension 48-month analysis from Yale, presented by Dr. Christopher van Dyck at AAIC 2025, showed lecanemab reduced progression to dementia by 56 percent over 4 years. Remarkably, 69 percent of low-tau early-stage patients had zero cognitive decline after 4 years of treatment. The safety profile also improved dramatically: 92 percent of ARIA events happened in the first 6 months, then dropped to placebo levels, meaning long-term lecanemab use is safer than initial trial data suggested once past the early window.

The TRAILBLAZER-ALZ 2 long-term extension from Eli Lilly, presented by John Sims, showed donanemab benefits doubled over time from 0.6 to 1.2 CDR-SB points between years 1 and 3. Starting treatment 18 months earlier produced 27 percent better outcomes than delayed treatment. The growing rather than plateauing benefit strongly suggests donanemab is actually modifying disease trajectory rather than temporarily slowing decline. This changes how clinicians should think about early intervention timing.

Obicetrapib is an oral CETP inhibitor originally developed as a cardiovascular cholesterol drug. In a study of 1727 patients with cardiovascular disease presented by Philip Scheltens from Amsterdam, APOE4/E4 carriers showed a 20 percent reduction in plasma pTau-217, an Alzheimer biomarker. This is the first oral medication to show specific Alzheimer-relevant biomarker benefit for E4 homozygotes. Because it is taken as a pill and already has a cardiovascular safety profile, it represents a potentially accessible alternative to monthly antibody infusions if benefits are confirmed.

The donanemab 3-year data showed that patients who started treatment 18 months earlier had 27 percent better outcomes than those who waited. The lecanemab data showed that 69 percent of low-tau patients, those with minimal existing pathology, had zero decline over 4 years. The pattern is clear: these drugs slow decline but cannot reverse existing damage, so the earlier you start, the less damage there is to manage. For APOE4 carriers, this argues strongly for early testing, early biomarker monitoring, and early access to treatment when warranted.

The growing evidence points toward yes. Historically these drugs were described as slowing decline by a modest amount, which critics called temporary symptomatic relief. But the 4-year lecanemab and 3-year donanemab extension data show benefits that grow over time rather than plateauing. If the drugs only provided temporary relief, the gap between treatment and placebo would stabilize. Instead, the gap widens, which is the signature of actual disease modification. This is a significant change in how the therapeutic class is understood.

ARIA, short for amyloid-related imaging abnormalities, includes ARIA-E (brain swelling) and ARIA-H (brain bleeding) caused by amyloid antibody therapies. With lecanemab, 92 percent of ARIA events happen in the first 6 months of treatment, after which the rate drops to placebo levels. This front-loaded risk profile means MRI monitoring is most important early, and patients who tolerate the first 6 months face dramatically lower ongoing risk. APOE4/E4 carriers still face the highest ARIA risk and require careful risk-benefit discussion before starting.